Informal consultation with manufacturers and WHO ad hoc working group on mouse protection models for acellular pertussis vaccines. National Institute for Biological Standards, 12 November 1998

Biologicals

Volumn 27, Issue 2, 1999, Pages 189-193

  Corbel, M J ^a   Xing, D K L ^a   Kreeftenberg, J G ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; DRUG FORMULATION; DRUG MECHANISM; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; LABORATORY TEST; METHODOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TOXICITY TESTING;

ANIMALIA; BORDETELLA PERTUSSIS;

EID: 0032696705     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1999.0209     Document Type: Short Survey

References (3)

1. Cherry JD, Gornbein J, Heininger U. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 16:1998;1901-1906.
2. Storsaeter J, Hallander HO, Gustafsson L. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 16:1998;1907-1916.
3. Oda M, Cowell JL, Burstyn DG. Protective activities of the filamentous hemagglutinin and the lympocytosis promoting factor of Bordetella pertussis in mice. J Infect Dis. 150:1984;823-833.